However, activation of the Akt survival pathway may counteract the cytotoxic effects of PARP inhibition and cause resistance to therapy (47), suggesting Akt pathway inhibition may enhance PARP inhibition in anti-tumor therapy. The gene discussed is PARP1; the disease is neoplasm.